Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Telomir Pharmaceuticals, Inc. (TELO) had Return on Tangible Equity of 1353.04% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-2.18M |
|
-- |
|
-- |
|
$2.19M |
|
$-2.19M |
|
$0.01M |
|
$-2.18M |
|
$-2.18M |
|
$-2.18M |
|
$-2.18M |
|
$-2.18M |
|
$-2.18M |
|
$-2.19M |
|
$-2.19M |
|
29.76M |
|
29.76M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$0.49M |
|
-- |
|
-- |
|
$0.49M |
|
$0.65M |
|
-- |
|
-- |
|
$0.65M |
|
$-0.16M |
|
$-0.16M |
|
$-0.16M |
|
29.76M |
|
| Cash Flow Statement Financials | |
$-0.86M |
|
-- |
|
-- |
|
$1.27M |
|
$0.40M |
|
$-0.86M |
|
$1.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
1353.04% |
|
|
Return on Tangible Equity |
1353.04% |
-443.79% |
|
1353.04% |
|
$-0.01 |
|
$-0.03 |
|
$-0.03 |
|